Anticoagulant Reversal Drugs Market, by Product Type (Idarucizumab, Protamine, Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021

Code : CMI4551

Pages :250

Formats :

Excel and PDF

Industry : Pharmaceutical

Anticoagulant Reversal Drugs MarketSize and Trends

The global anticoagulant reversal drugs market is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9% during the forecast period (2021-2028)

Figure 1. Global Anticoagulant Reversal Drugs Market Share (%) in Terms of Value, By Product Type, 2021

Key players operating in the global anticoagulant reversal drugs market are focusing on acquisitions and mergers, which is expected to drive the market growth.

Increasing acquisition provides the opportunity to expand commercial range of anticoagulant reversal drugs, which is expected to drive the market growth during the forecast period. For instance, in May 2020, Alexion Pharmaceuticals, Inc. announced acquisition of Portola Pharmaceuticals, Inc. The acquisition includes Andexx [coagulation factor Xa (recombinant), inactivated-zhzo], branded as Ondexxya, a Factor Xa inhibitor reversal medication. Alexion Pharmaceuticals, Inc. acquired Portola through a tender offer and subsequent merger with Odyssey Merger Sub Inc. Near-term diversification will be added by this acquisition to Alexion’s commercial portfolio.

Figure 2. Global Anticoagulant Reversal Drugs Market Share (%), By Distribution Channel, 2021